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Abstract
Background: Lactic acidosis (LA) and severe  hyperlactataemia  (HL)  are  infrequent  but
serious complications of antiretroviral therapy which have  been  associated  with  a  high
fatality rate.
Methods: In a multinational retrospective cohort study LA was  defined  as  arterial  blood
pH <7.35, bicarbonate <20 mmol/l and lactate above normal and HL as  confirmed  blood
lactate >5 mmol/l. Logistic regression was used to identify factors associated with fatality.
Sensitivity  and  specificity  of  different  case  definitions  as   predictor   of   death   were
compared.
Results: The overall case-fatality rate was 19/110 (17.3%) but among acidotic  patients  it
was 33% (16/49 cases). There were 10 asymptomatic patients and none of them died  as
consequence of the event.  The median lactate for fatal,  non-fatal  and  all  patients  was
8.3  mmol/l  (IQR=7.2-13.1),  6.4  mmol/l  (IQR=5.4-7.8)  and  6.7  mmol/l   (IQR=5.5-8.1)
respectively.  After  adjusting  for  age  and  current  CD4  cell  count,  lactate  >7  mmol/l
(OR=6.27; 95%CI=1.13-34.93), blood bicarbonate <12 mmol/l (OR=10.02 relative to  >18
mmol/l;   95%CI=1.33-75.65)    and    concurrent    opportunistic    infections    (OR=8.69;
95%CI=1.45-52.22) were independently associated with  case  fatality.  Blood  lactate  >7
mmol/l  showed  a  sensitivity  of  84%  for  fatality  with  a  specificity  of   60%   whereas
bicarbonate <12 mmol/l showed a better specificity (85%) but a poorer  sensitivity  (42%).
Bicarbonate <18 mmol/l appears  to  be  as  good  as  lactate  <7  mmol/l  at  predicting  death
(sensitivity 90%; specificity 54%).
Conclusions: Our data suggest that a blood lactate >7 mmol/l and blood bicarbonate  <18
mmol/l appear to predict death and might help clinicians  in  selecting  patients  who  may
benefit from more intense monitoring.
Introduction
Lactic acidosis (LA) and severe hyperlactataemia (HL) are infrequent but serious adverse
drug  reactions   attributed   to   dideoxynucleosides.   In   well-resourced   countries   the
incidence of HL/LA has decreased substantially over time, mainly because of changes  in
anti-retroviral therapy (ART) prescription patterns (1). However, the expanding access  to
ART in resource-limited regions has caused an important rise in the  reported  number  of
adverse reactions attributable to dideoxynucleosides (2;3). Incidence  rates  of  HL/LA  in
South Africa have been reported as ranging from 10–19 cases per 1000 person-years on
ART (2;4;5) versus  0.8–8.7  cases  per  1000  person-years  on  ART  in  well-resourced
countries (6). This apparent higher incidence of HL/LA in resource-limited countries might
mainly be because stavudine (d4T)  is  often  part  of  the  first  line  combination  therapy
available in most countries. However, previously reported risk factors for HL/LA  such  as
female gender and advanced HIV-induced immunosuppression are also more frequent in
resource-limited settings (3;7).
Another factor which may explain in part the differences in incidence  of  HL/LA  between
studies  is  the  lack  of  a  universally  accepted   case   definition   for   hyperlactataemic
conditions  in  HIV-infected  patients.   Most   case   definitions   proposed   combine   the
presence of symptoms along with abnormal blood lactate levels to make a  diagnosis  (8-
10)..
Although  previous  case-series  and  observational  studies  have  shown   fatality   rates
ranging between 15 to 60% (11-14), little is known about specific  risk  factors  for  fatality
among patients with HL/LA. Observational studies have found  blood  lactate  levels  >10
mmol/l and low bicarbonate to be associated with fatal  outcome  in  patients  with  LA/HL
(5;13;15).
Previously, in a large multinational case-control study we  examined  the  risk  factors  for
HL/LA. No analyses of the risk  factors  associated  with  mortality  were  performed  (16).
The aim of this study was to identify factors associated with a fatal outcome in  the  same
study population.
Participants and methods
All participants who met the criteria for HL/LA in our  multinational  case-control  study  to
identify risk factors for these complications in HIV-infected adults  exposed  to  ART   (16)
were  included  in  this   retrospective   cohort   analysis.   In   the   parent   study   severe
hyperlactataemia (HL) was  defined  as  confirmed  blood  lactate  >5  mmol/l,  and  lactic
acidosis (LA) as  blood  pH  <7.35,  bicarbonate  <20  mmol/l  and  lactate  above  normal
range. Arterial gases, pH and bicarbonate were not measured in all patients with HL.
The  aim  of  the  present  analysis  was  to  identify  factors  associated  with  fatality   by
comparing patients that died as a consequence of the event to patients  who  survived  it.
Demographics, clinical data on HIV infection, full ART exposure  history,  and   acid-base
balance  and  blood  lactate  laboratory  values  at  the  time   of   event   diagnosis   were
recorded. Information on previous or concurrent ART-induced adverse reaction was  also
collected. Body mass index was not included in the analysis because  data  on  height  of
most patients was not available.
Statistical  analysis  was  performed  using  Stata  version  10.1  (StataCorp  LP,  College
Station,  Texas,  USA).   Quantitative   variables   were   summarised   as   medians   and
compared  using  the  Mann-Whitney  test.  Categorical   variables   were   presented   as
proportions  and  compared  using  Fisher’s  exact  test.  A  logistic  regression  model  to
identify factors associated with fatality was built including those  factors  found  significant
(P<0.05) in the univariate analysis. Exact logistic regression was also used  to  deal  with
zero cells in the analysis when required (17). Logistic regression was used because of its
good statistical. Sensitivity and specificity of different variables as predictor of death were
compared. Receiver operating characteristic (ROC) curves were  also  used  to  examine
the specificity and sensitivity at different thresholds of the measure. We would consider a
variable as  good  predictor  of  death  if  its  sensitivity  is  not  lower  than  80%  and  the
specificity is >50%.
Ethical  approval  was  obtained  from  all   relevant   ethics   committees,   including   the
Multicentre  Research  Ethics  Committee  of  London.  Written   informed   consent   was
obtained from study participants when requested by the relevant ethics committee.
Results
A  total  of  110  patients  were  included  (49  with  LA),  of  which  19  died  (17%)  as   a
consequence of the event a median  8  days  (Interquartile  range  –IQR–  3  to  16)  after
diagnosis. However, 16 out of the 19 patients who died had LA, so the  case  fatality  rate
among acidotic patients was  33%  (16/49  cases).  There  was  no  association  between
either age, gender or ethnic background and death (Table 1). The median  age  of  those
who died was 41.3 years (IQR=37.8–49.2) and 42.8 years (IQR=35.9–53.8) for  non-fatal
patients (P=0.737). There was no significant difference in the median CD4  cell  count  at
the  time  of  the   diagnosis   of   the   event   in   fatal   versus   non-fatal   patients   (188
cells/mm3 (IQR=89–370) and 253 cells/mm3 (IQR=144–360), respectively (P=0.242).
The median blood lactate at the time  of  diagnosis  was  8.3  mmol/l  (IQR=7.2–13.1)  for
fatal cases and 6.4 mmol/l (IQR 5.4 – 7.8) for those who  survived  the  event  (P<0.001).
Patients who died with LA had a median lactate of  8.6  mmol/l  (IQR=7.2–13.8)  whereas
the three patients who died with HL had lactate values of  7.6,  8.1  and  11.4  mmol/l.  All
these fatal HL patients also had low bicarbonate levels (17-18 mmol/l)  but  arterial  blood
pH was not measured. There were seven patients with LA who had  lactate  readings  <5
mmol/l at the time of diagnosis but lactate ranged between 5.6 and 20.3 mmol/l  in  those
who died.
The median blood bicarbonate was significantly lower in  patients  who  died  (median  12
mmol/l;   IQR=8.2–17)   compared   to   those   who   survived    (median    18.9    mmol/l;
IQR=14.7–22.2)  (P<0.001).  Blood  lactate  levels  were  monitored  routinely  as  part  of
normal patient care in five of the 19 participating centres. The frequency  of  case  fatality
was not different in patients enrolled in  centres  where  lactate  was  routinely  measured
(7/36; 19%) compared to those  in  centres  where  it  was  not  (12/74;  16%)  (P=0.789).
Arterial blood pH was reported in 78 patients, 16 of whom  died  as  consequence  of  the
event (21%).The median pH for fatal patients  was  7.23  (95%CI=7.11–7.31)  whereas  it
was 7.35 (95%CI=7.30–7.41) for non-fatal patients (P<0.001). Because arterial blood  pH
was not reported in a significant number of  cases  with  HL,  it  was  not  included  in  the
multivariate model.
Most of the patients were  receiving  dideoxynucleoside-based  ART  at  the  time  of  the
event. However, the proportion of patients who died on dideoxynucleosides (12/19; 63%)
was somewhat lower than the  proportion  of  patients  with  non-fatal  episodes  on  such
drugs  (78/91;  86%)  (P=0.043).  Of  the  seven  fatal  patients  who  were  not  receiving
dideoxynucleosides at the  time  of  the  event  three  ceased  d4T  four  to  seven  weeks
before  the  event,  and  four  were   receiving   zidovudine/lamivudine   (AZT/3TC)-based
combinations and had  never  been  exposed  to  dideoxynucleosides  in  the  past.  Most
patients  had  gastro-intestinal  (64%)  or  constitutional  symptoms  (57%)   although   no
symptoms  were  reported  in  10  patients  (9%).  These  asymptomatic  patients  had   a
median blood lactate of 5.8 mmol/l (range 5.1-7.3).
A sensitivity analysis using different threshold values for blood lactate as  a  dichotomous
variable   was   conducted.   Fitting   the   same   model   adjusted   by   age,   concurrent
opportunistic  infections  and  current  CD4  cell  count,  but  varying   the   blood   lactate
threshold, a value of 7 mmol/l resulted in the  highest  model  likelihood  (Table  2).  ROC
curves were constructed to assess the appropriateness of  different  thresholds  of  blood
lactate or bicarbonate to construct binary predictors of  death.  There  was  no  difference
between the area under the curve (AUC) calculated for these variables. Levels of  lactate
ranging from 7.27 to 8.1 mmol/l as well as levels of bicarbonate ranging between 11  and
14 mmol/l appear to be good choices for cut-off in predicting death.
The  model  presented  in  table  3  shows  a  significant   and   independent   association
between  lactate  levels  7-10  mmol/l  and  fatality  when  compared  to  with  <7   mmol/l
(OR=6.27; 95%CI=1.13-34.93). In addition,  bicarbonate  levels  <12  mmol/l  showed  an
OR for death of 10.02 (95%CI=1.33-75.65). There was some  evidence  of  an  increased
death rate for bicarbonate  12-18  mmol/l  (OR=5.82;  95%CI=  0.76-44.89).  A  sensitivity
analysis was performed including only those individuals  initially  diagnosed  with  LA.  All
the variables found to  be  independently  associated  with  fatality  in  the  main  analysis
showed similar effects, both in terms of  the  magnitude  and  the  direction  of  it.  Among
patients  with   LA,   blood   lactate   7–10   mmol   (OR=6.24;   95%CI=0.78–49.61)   and
concurrent OI (OR=5.68; 95%CI=0.74–43.69) appeared to be  somehow associated  with
fatality. The effect of blood bicarbonate is less clear as, by definition, all patients had  low
bicarbonate   at   entry   (median   11.95   mmol/l   –IQR=8.2-13.95–   and   14.7    mmol/l
–IQR=11.0-13.95 – for fatal and non-fatal patients respectively).  Similarly, no differences
were seen in the direction of the association between any of the variables  analysed  and
death when  the  analysis  was  restricted  to  patients  from  centres  where  lactate  was
routinely measured compared to those in centres where it was not (data not shown).
No  symptom-free  patient  was  acidotic  or  died,  so  absence  of   symptoms   perfectly
predicted survival.  No  association  was  found  between  the  presence  of  any  specific
symptom and fatality. When the analysis was limited to symptomatic  patients  there  was
no  change  on  the   magnitude   of   the   association   between   factors   independently
associated with death in the general model (data not shown). To explore  the  association
between the presence of symptoms and death an  exact  logistic  regression  model  was
fitted (17). After adjusting by blood levels of lactate and bicarbonate, concurrent OI,  CD4
cell count and age, the estimated association between symptoms and fatal outcome  was
inconclusive  (OR  0.39;  95%CI  0.03  –  Infinity)  because  our  study  included  too   few
asymptomatic patients (Table 4).
As shown on table 5, the specificity of a model combining  blood  lactate  >7  mmol/l  and
bicarbonate <12 mmol/l was 90%  to  predict  fatality,  although  its  sensitivity  was  37%.
Blood lactate  >7  mmol/l  showed  a  specificity  of  60%  but  with  a  sensitivity  of  84%.
Similarly, bicarbonate <18 mmol/l showed a very high sensitivity (90%) with  a  specificity
similar  to  the  figure  calculated  for  lactate  >7  mmol/l  (54%).  On   the   contrary,   the
sensitivity of blood bicarbonate <12 mmol/l was 42%.
Discussion
Our study showed an overall fatality rate of 17% but, in  patients  with  demonstrated  LA,
the rate was 33%. This was similar to the 33% reported in a Spanish case-series  and   a
retrospective cohort study in Soweto, South Africa, where seven of  the  23  patients  with
LA died  (30%)  (2;13).  Slightly  lower  rates  have   been  reported  in  recent  studies  in
Uganda and Cape Town, South Africa where five of 24 cases (21%) and 11 of  73  cases
(15%) of LA died, respectively (14;18).
Two small European cohort  studies  of  symptomatic  HL  showed  that  only  those  who
eventually developed LA died (19;20). It has been suggested that HL may progress to LA
if the offending drug is not discontinued (9;21). There is little  evidence  of  HL  leading  to
death unless acidosis is also present. None of the 44 cases of symptomatic  HL  included
in a South African study died (2). In our  study,  the  exact  cause  of  death  of  the  three
patients  with  HL  who  died  within  two  weeks  after  diagnosis  was  not  recorded  and
therefore,  we  cannot  exclude  the  possibility  of  other  conditions  contributing   to   the
outcome. However, some patients in the HL group had blood lactate  levels  >10  mmol/l,
which have been proposed as suggestive  of  acidosis  (8).  Therefore,  some  of  the  HL
cases in whom  blood  pH  was  not  measured  may  have  had  acidosis  at  the  time  of
diagnosis.
Most  reports  of  HL/LA  in  HIV-infected  adults  include  only  patients  with   suggestive
symptoms but our study shows that patients with confirmed HL (blood lactate >5  mmol/l)
can be asymptomatic or have symptoms mild enough to not be reported. In contrast, in  a
prospective cohort study John et al. found that all patients (5/349) who ever had  a  blood
lactate  >5   mmol/l   were   clearly   symptomatic   (22).   It   has   been   suggested   that
asymptomatic HL may be due to spurious results from an inappropriate   blood  collection
technique (23). However, it is unlikely that incorrect management of blood samples would
produce  consistent  blood  lactate  levels  >5  mmol/l.   Nevertheless,   because   of   the
retrospective nature of this study,  it  is  not  possible  to  exclude  the  possibility  of  mild
symptoms not being reported and or not being recorded in patient records.
Two previous studies have found lactate levels >10 mmol/l as  independently  associated
with death in patients with HL/LA (13;15). Our study included a higher number of fatalities
than those previously reported and this provides greater power to assess the  association
between lactate and fatality. In  our  study  blood  lactate  >7  mmol/l  was  independently
associated with death. Although, the lactic acidemia definition (8) showed a sensitivity  of
100% (95%CI 82-100) for fatality its specificity was quite poor as 94% of non-fatal  cases
also had lactate >5 mmol/l. The sensitivity of lactate >7 mmol/l was 84% but had a  better
specificity than the lactic acidemia definition  (60%).  Adding  bicarbonate  <12  mmol/l  to
lactate >7 mmol/l increased its specificity to 90% but decreased its sensitivity from  90  to
40%. Compared with the lactic acidemia definition, a combined definition based on  blood
lactate (>7 mmol/l) and bicarbonate  (<12  mmol/l)  as  well  as  blood  lactate  >7  mmol/l
alone showed a better specificity for fatality (Table 5). Although most patients with  HL/LA
would recover after stopping exposure to the  offending  drugs,  those  with  more  severe
episodes (i.e. those more likely to die)  may  benefit  from  more  intense  monitoring  and
additional   interventions.   Given   the   cost   implications   of    intense    follow-up    and
management for severe cases, a definition with the highest possible specificity  would  be
ideal because  it  would  reduce  the  number  of  false  positives  to  a  minimum.  In  that
context, blood lactate >7 mmol/l appeared to be  a  good  predictor  for  fatality  with  high
sensitivity and 60% specificity.
Stead et al., with 12  fatal  cases  in  89  cases  in  a  South  African  retrospective  cohort
analysis, reported a significant association  between  low  blood  bicarbonate  levels  and
death (5). In our study, after adjusting for other variables and  potential  confounders,  the
association between blood bicarbonate <12 mmol/l and fatality  was  evident  (OR=10.02;
95%CI=1.33-75.65)  when  compared  to  those  patients  with   bicarbonate   levels   >18
mmol/l.  However,  according  to  our  results  bicarbonate  <12  mmol/l  may  be  a  weak
predictor for fatality on its own because of its poor sensitivity. Nevertheless, based on the
calculated sensitivity and specificity for fatality (90%  and  54%  respectively),  it  appears
that bicarbonate <18 mmol/l may be as good as  lactate  >7  mmol/l  in  predicting  death.
Furthermore,  there  was  some  evidence  suggesting  a  possible  association   between
bicarbonate ranging between 12 and18  mmol/l  and  fatality  (OR=  5.82;  95%CI=  0.76-
44.89) in the multivariate analysis.
In  this  study,  concurrent  OI  were  independently  associated  with  fatal  outcome.   No
association between fatality and markers of  immunosuppression  has  been  reported  in
previous studies. However, it has  also  been  suggested  that  acute  bacterial  infections
may induce LA in patients with high baseline  blood  lactate  levels  (21).  As  we  did  not
record the precise  cause  of  death  we  cannot  exclude  the  possibility  that  concurrent
infections played  an  important  role  in  inducing  LA  leading  to  death  in  patients  with
previously compensated HL.
Although a number of studies have suggested an increased risk  for  HL/LA  in  non-white
populations  compared to white ones (2;4;16;24) we found no association between ethnic
background and death. Similarly, fatality rates reported in African studies  are  not  higher
than those found in Europe (2;4;13;14). Therefore, one could assume that  even  if  some
ethnic groups may be at higher risk for HL/LA when exposed to  dideoxynucleosides,  the
outcome of their event is not necessarily worse than for white Europeans.
Most of the proposed classifications for blood lactate  disorders  in  HIV-infected  patients
have used a threshold of 10 mmol/l  to  either  make  a  diagnosis  of  severe  HL  (10)  or
classify a  case  of  “lactic  acidemia”  regardless  of  the  presence  of  symptoms  (8;25).
However, in the light of results of our study, it may  be  pertinent  to  consider  a  different
threshold value, as patients with blood lactate >7 mmol/l might be at a  significant  risk  of
dying. Although we have found asymptomatic patients  with  confirmed  blood  lactate  >5
mmol/l, our  data  cannot  be  used  to  assess  accurately  the  association  between  the
presence of symptoms and fatality as none of the asymptomatic  patients  died  and  only
9% of the included  patients  were  symptoms  free.  However,  the  association  between
lactate or bicarbonate levels and death appeared to remain at  the  same  level  predicted
by the logistic regression model even after adjusting for the presence of symptoms in  the
exact logistic regression model (Table 4).
Using specific threshold values of blood lactate and/or bicarbonate  levels  would  require
regular monitoring of blood samples. A targeted  approach  might  be  appropriate  i.e.  in
those  individuals  particularly  at  risk  for  HL/LA  such  as  female   patients,   obese   or
overweight individuals, those  with  advanced  HIV-induced  immunosuppression,  elderly
patients   and   probably,   those   from   non-white   ethnic   origin   who    are    receiving
dideoxynucleoside-based  ART  (1;2;5;16).  Point-of-care  blood  lactate  analysers  have
been   successfully   used    in    resource-limited    settings    to    monitor    patients    on
dideoxynucleoside-based therapies (26;27). In addition, in some middle-income countries
standard bicarbonate is measured in patients with symptoms suggestive of HL (5).
Our study has some limitations. Patients were mostly from well resourced  countries  and
so our results may be limited in their generalisability to resourced  limited  settings  where
the dideoxynucleosides (a stavudine and didanosine) are still widely used.  However, our
cases  were  diagnosed  between   1997   and   2003   when   dideoxynucleosides   were
frequently  used  in  well  resourced  countries,  the  fatality   rates   reported   by   African
investigators do not differ from rates reported in European studies and ethnic  origin  was
not associated with fatality in  our  analysis.   Patients  were  diagnosed  with  HL/LA  and
followed-up in different centres which had diverse  policies,  therefore,  the  availability  of
data  was  not  uniform  across  the  study  population.   Blood  lactate  was  not  routinely
monitored in all participant centres; therefore some patients  may  have  been  tested  for
lactate  because  of  the  presence  of  symptoms,  exposure  to   dideoxynucleosides   or
presence of another medical condition.  However, we could not find any major  difference
between  patients  routinely  tested  for  lactate  and  those  who  were  not  except  for  a
stronger association between fatality and concurrent OI in patients not routinely tested for
lactate.  We did not collect data  on  cause  of  death,  therefore  we  cannot  exclude  the
contribution   of   other   factors    to    the    outcome.    Finally,    patients    exposed    to
dideoxynucleosides tend to develop HL/LA within few months, so long-term  exposure  to
ART on the cohorts where patients  were  extracted  from  may  impact  HL/LA  incidence
rate. However, because patients  were  identified  retrospectively  with  non  limitation  on
calendar period, the age of the cohort should have no  major  impact  on  incidence.   Our
study could not assess the effect of BMI on fatality.
In summary, patients with confirmed severe hyperlactataemia  can  be  asymptomatic.  In
addition, blood bicarbonate <12 mmol/l, lactate >7 mmol/l and concurrent OI appeared to
be associated with death in patients with HL/LA.  Blood  lactate  >7  mmol/l  and  perhaps
bicarbonate <18 mmol/l can predict death and  may  help  to  identify  patients  who  may
benefit from more intense monitoring.
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